{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:44:55Z","timestamp":1775123095231,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Xinjiang Uygur Autonomous Region Natural Science Foundation Project"},{"name":"Autonomous Region Health Youth Medical Science and Technology Talent Special Research Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02134-2","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:58:23Z","timestamp":1775044703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen"],"prefix":"10.1007","volume":"26","author":[{"family":"Linzhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maimaitirexiati","family":"Xianmusiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"2134_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, WagleN S et al. Cancer Statistics, 2023[J]. CA: A Cancer Journal for Clinicians, 2023,73(1): 17\u201348.","DOI":"10.3322\/caac.21763"},{"issue":"1","key":"2134_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pathol.2019.08.013","volume":"52","author":"N Sukswai","year":"2020","unstructured":"Sukswai N, Lyapichev K, Khoury JD, et al. Diffuse large B-cell lymphoma variants: an update [J]. Pathology. 2020;52(1):53\u201367.","journal-title":"Pathology"},{"issue":"7","key":"2134_CR3","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1182\/bloodadvances.2021004618","volume":"6","author":"K MIYAWAKI","year":"2022","unstructured":"MIYAWAKI K, KATO K, SUGIO T, et al. A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL[J]. Blood Adv. 2022;6(7):2388\u2013402.","journal-title":"Blood Adv"},{"issue":"17","key":"2134_CR4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase \u2161 study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma[J]. J Clin Oncol. 2013;31(17):2103\u20139.","journal-title":"J Clin Oncol"},{"key":"2134_CR5","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","volume":"110","author":"NM PolettoS","year":"2022","unstructured":"PolettoS NM. Treatment strategies for patients with diffuse large B-cell lymphoma[J]. Cancer Treat Rev. 2022;110:102443.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2134_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","volume":"14","author":"Y CHU","year":"2021","unstructured":"CHU Y, ZHOU X, WANG X. Antibody-drug conjugates for the treatment of lymphoma: clinicaladvancs and latest progress [J]. J Hematol Oncol. 2021;14(1):88.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2134_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2217\/fon-2017-0498","volume":"14","author":"R ZHANG","year":"2018","unstructured":"ZHANG R, LIU Q, LIAO Q, et al. CD59: A promising target for tumor immunotherapy[J]. Future Oncol. 2018;14(8):781\u201391.","journal-title":"Future Oncol"},{"issue":"11","key":"2134_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41419-019-2065-4","volume":"10","author":"ZHANG Ronghua","year":"2019","unstructured":"Ronghua ZHANG, Qiaofei LIU, Junya PENG, et al. Pancreatic cancer-educated macrophages protect cancer cells from complement dependent cytotoxicity by up regulation of CD59[J]. Cell Death Dis. 2019;10(11):836.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2134_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/cbf.3487","volume":"38","author":"M ABDEL-LATIF","year":"2020","unstructured":"ABDEL-LATIF M, Suzan SAIDAN. Coenzyme Q10 attenuates rat hepatocarcinogenesis via the reduction of CD59 expression and phospholipase D activity[J]. Cell Biochem Funct. 2020;38(4):490\u20139.","journal-title":"Cell Biochem Funct"},{"key":"2134_CR10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fimmu.2019.01074","volume":"10","author":"A GELLER","year":"2019","unstructured":"GELLER A, YAN J. The role of membrane bound complement regulatory proteins in tumor development and cancer immunotherapy[J]. Front Immunol. 2019;10:1074.","journal-title":"Front Immunol"},{"issue":"1","key":"2134_CR11","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"2134_CR12","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin\u2043fixed paraffin\u2043embedded tissue biopsies[J]. J Clin Oncol. 2015;33(26):2848\u201356.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2134_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A DAVIES","year":"2019","unstructured":"DAVIES A, CUMMIN T E BARRANSS, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial [J]. Lancet Oncol. 2019;20(5):649\u201362.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2134_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41408-021-00542-z","volume":"11","author":"SH DESAI","year":"2021","unstructured":"DESAI SH, MACON W R LAPLANTB, et al. Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the phase 2 MC078E study [J]. Blood Cancer J. 2021;11(9):160.","journal-title":"Blood Cancer J"},{"issue":"4","key":"2134_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H TILLY","year":"2022","unstructured":"TILLY H, MORSCHHAUSER F, SEHN L H, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma [J]. N Engl J Med. 2022;386(4):351\u201363.","journal-title":"N Engl J Med"},{"issue":"9","key":"2134_CR16","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.3390\/ijms23095208","volume":"23","author":"S Katharina","year":"2022","unstructured":"Katharina S, Peter A, Gerhard S. Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab[J]. Int J Mol Sci. 2022;23(9):5208.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2134_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0167-5699(99)01537-6","volume":"20","author":"A Gorter","year":"1999","unstructured":"Gorter A, Meri S. Immune evasion of tumor cell using membrane-bound complement regulatory proteins[J]. Immunol Today. 1999;20(12):576\u201382.","journal-title":"Immunol Today"},{"issue":"1","key":"2134_CR18","doi-asserted-by":"publisher","first-page":"8652","DOI":"10.1038\/s41598-022-12692-6","volume":"12","author":"SW Son","year":"2022","unstructured":"Son SW, Cho E, Cho H, et al. NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59[J]. Sci Rep. 2022;12(1):8652.","journal-title":"Sci Rep"},{"key":"2134_CR19","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.2147\/OTT.S248065","volume":"13","author":"AIL SUN X J","year":"2020","unstructured":"SUN X J AIL. FENG Y C.The value of ABO blood group and complete blood count for the prognosis analysis of gastric cancer patients[J]. Onco Targets Ther. 2020;13:4627\u201333.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2134_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.5858\/arpa.2013-0064-OA","volume":"138","author":"Y Shang","year":"2014","unstructured":"Shang Y, Chai N, Gu Y, et al. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer[J]. Arch Pathol Lab Med. 2014;138(7):910\u201319.","journal-title":"Arch Pathol Lab Med"},{"key":"2134_CR21","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-10-3016","volume":"71","author":"W Hu","year":"2011","unstructured":"Hu W, Ge X, You T, et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis[J]. Cancer Res. 2011;71:2298\u2013307.","journal-title":"Cancer Res"},{"key":"2134_CR22","first-page":"6209","volume":"13","author":"J Wang","year":"2020","unstructured":"Wang J, Li Z, Wang L, et al. CD59 promotes the proliferation and metastasis of gastric cancer via the PI3K\/AKT pathway[J]. Onco Targets Ther. 2020;13:6209\u201321.","journal-title":"Onco Targets Ther"},{"key":"2134_CR23","doi-asserted-by":"crossref","unstructured":"Manning BD, Toker A. AKT\/PKB Signalling: Navigating Network[J]. Cell. 2017;169(3):381\u2013405.","DOI":"10.1016\/j.cell.2017.04.001"},{"issue":"6","key":"2134_CR24","first-page":"a016360","volume":"6","author":"MS Hayden","year":"2014","unstructured":"Hayden MS, Ghosh S. Regulation of NF-\u03baB by TNF family cytokines[J]. Cold Spring Harb Perspect Biol. 2014;6(6):a016360.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2134_CR25","doi-asserted-by":"crossref","unstructured":"Hientz K, Mohr A, Bhakta-Guha D et al. The role of p53 in cancer drug resistance and targeted chemotherapy[J].Oncotarget. 2017;8(5):8921\u201346.","DOI":"10.18632\/oncotarget.13475"},{"issue":"7","key":"2134_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/1568009614666140818211103","volume":"14","author":"G Song","year":"2014","unstructured":"Song G, Song G, Ni H, et al. Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP[J]. Curr Cancer Drug Targets. 2014;14(7):659\u201370.","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02134-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02134-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02134-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:46:04Z","timestamp":1775119564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02134-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2134"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02134-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study, including retrospective data extraction and all additional research tests (like CD59 IHC), was conducted after obtaining approval from the Ethics Committee of the Affiliated Tumor Hospital of Xinjiang Medical University (Approval Number: [K-2021062]).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All procedures strictly adhered to ethical standards, ensuring patient data confidentiality and appropriate use.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"212"}}